Atlas Venture, a Cambridge, Mass.-based early stage venture capital firm investing in biotech innovation, closed its twelfth fund, at $400m.
Atlas Venture will continue to focus on building biotech companies to deliver high-impact therapies to patients. Partnering with experienced entrepreneurs-in-residence, the firm creates new startups focused on innovation, sourced from global institutions and the team’s entrepreneurial networks.
Its in-house incubation space in Kendall Square enables Atlas’ team to be hands-on collaborators with companies from inception through the goal of creating new medicines.
With the closing of Fund XII, Michael Gladstone was promoted to partner. Gladstone joined Atlas in 2012 and has been a key contributor to many portfolio companies over the last eight years, including Akero, AVROBIO, Delinia, IFM, and others.
Alongside Gladstone, the six investing partners in Fund XII also include Jason Rhodes, Bruce Booth, Kevin Bitterman, Jean-François Formela, and David Grayzel.
FinSMEs
05/06/2020